Drugs / CAM-H2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04467515 | Sep 2021 → Dec 2023 | HER2 positive breast carcinoma | Precirix | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAM-H2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04467515 ↗ |
| Route | Intravenous | “each cycle given as 2 IV administrations, 4 weeks apart” NCT04467515 ↗ |